Search Results - "DUBINSKY, M. C."

Randomised clinical trial: individualised vs. weight‐based dosing of azathioprine in Crohn's disease by Dassopoulos, T., Dubinsky, M. C., Bentsen, J. L., Martin, C. F., Galanko, J. A., Seidman, E. G., Sandler, R. S., Hanauer, S. B.

“…Summary Background Azathioprine (AZA), a pro‐drug metabolised to the active metabolites 6‐tioguanine nucleotides (6TGN), is a steroid‐sparing therapy for…”
Get full text

Differences in the management of Crohn’s disease among experts and community providers, based on a national survey of sample case vignettes by ESRAILIAN, E., SPIEGEL, B. M. R., TARGOWNIK, L. E., DUBINSKY, M. C., TARGAN, S. R., GRALNEK, I. M.

“…Summary Background  When faced with the same set of facts, healthcare providers often make different diagnoses, employ different tests and prescribe disparate…”
Get full text

Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease by Dubinsky, Marla C., Lamothe, Stéphanie, Yang, Hui Ying, Targan, Stephan R., Sinnett, Daniel, Théorêt, Yves, Seidman, Ernest G.

“…Background & Aims: The effects of 6-mercaptopurine (6-MP) are mediated via its intracellular conversion to 6-thioguanine (6-TG) and 6-methylmercaptopurine…”
Get full text

A validated web‐based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables by Siegel, C. A., Horton, H., Siegel, L. S., Thompson, K. D., Mackenzie, T., Stewart, S. K., Rice, P. W., Stempak, J. M., Dezfoli, S., Haritunians, T., Levy, A., Baek, M., Milgrom, R., Dulai, P. S., Targan, S. R., Silverberg, M. S., Dubinsky, M. C., McGovern, D. P.

“…Summary Background Early treatment for Crohn's disease (CD) with immunomodulators and/or anti‐TNF agents improves outcomes in comparison to a slower ‘step up’…”
Get full text

Editorial: how to interpret risks and prediction of complications in Crohn's disease – can our patients interpret them? Authors' reply by Siegel, C. A., Dubinsky, M. C.

Get full text

New patients: should children be treated differently? by Dubinsky, M. C.

“…Inflammatory bowel disease (IBD) in childhood is often diagnosed at a vulnerable time of growth and development, and is recognized as one of the most…”
Get full text

Exploring Disease Remission and Bowel Urgency Severity Among Adults with Moderate to Severe Ulcerative Colitis: A Qualitative Study by Dubinsky, Marla C, Newton, Louise, Delbecque, Laure, Hunter, Theresa, Guobyte, Aiste, Naegeli, April N, McFadden, Shehan, Donaldson, Jill, Symonds, Tara, Lewis, James D

“…Achieving and maintaining symptom control is a key treatment goal in ulcerative colitis (UC). Bowel urgency is an important symptom of UC, thus measurement of…”
Get full text

Serum Immune Responses Predict Rapid Disease Progression among Children with Crohn's Disease: Immune Responses Predict Disease Progression by DUBINSKY, Maria C, LIN, Ying-Chao, ISRAEL, David, BAHAR, Ron, CHRISTIE, Dennis, WAHBEH, Ghassan, SILBER, Gary, DALLAZADEH, Saied, SHAH, Praful, THOMAS, Danny, KELTS, Drew, HERSHBERG, Robert M, DUTRIDGE, Debra, ELSON, Charles O, TARGAN, Stephan R, TAYLOR, Kent D, ROTTER, Jerome I, HUIYING YANG, PICORNELL, Yoana, LANDERS, Carol J, FARRIOR, Sharmayne, WROBEL, Iwona, QUIROS, Antonio, VASILIAUSKAS, Eric A, GRILL, Bruce

“…Crohn's disease (CD) is a heterogeneous disorder characterized by diverse clinical phenotypes. Childhood-onset CD has been described as a more aggressive…”
Get full text

Pneumatosis intestinalis and colocolic intussusception complicating Crohn's disease by Dubinsky, M.C, Deslandres, C, Patriquin, H, Seidman, E.G

Get full text

Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease by Dubinsky, Marla C, Ofman, Joshua J, Urman, Marnina, Targan, Stephan R, Seidman, Ernest G

“…Confronted with nonspecific symptoms, accurate screening tests would be useful to clinicians to distinguish between functional childhood disorders and…”
Get full text

An open‐label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6‐mercaptopurine therapy by Dubinsky, Marla C., Hassard, Philip V., Seidman, Ernest G., Kam, Lori Y., Abreu, Maria T., Targan, Stephan R., Vasiliauskas, Eric A.

“…Background and Aims A substantial number of patients with inflammatory bowel disease (IBD) fail to achieve a complete clinical response with 6‐mercaptopurine…”
Get full text

P381 Ustekinumab trough levels are associated with sonographic transmural healing in Pediatric Inflammatory Bowel Disease by Kellar, A, Aronskyy, I, Dubinsky, M C, Dolinger, M T

Get full text

Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease by Kappelman, Michael D., Weaver, Kimberly N., Boccieri, Margie, Firestine, Ann, Zhang, Xian, Long, Millie D., Chun, K., Fernando, M., Zikry, M., Dai, X., Watkins, R., Adler, J., Dubinsky, M.C., Kastl, A., Bousvaros, A., Strople, J.A., Cross, R.K., Higgins, P.D.R., Ungaro, R., Bewtra, M., Bellaguarda, E., Farraye, F.A.

Get full text

P759 Understanding how patients with moderate-to-severe Crohn’s disease describe the spectrum of bowel urgency definitions: Results from qualitative research by Dubinsky, M C, Hunter Gibble, T, Stassek, L, Harding, G, Stefan, M, Fikre, T, Potts Bleakman, A, Moses, R

Get full text

P720 Exit interviews exploring Crohn’s disease patients’ experience of changes in their bowel urgency during the mirikizumab Phase 3 clinical trial in adult patients with moderate to severe Crohn disease by Gibble, T H, Macey, J, Makin, H, Rosu, R, Mellor, K, Kitchen, H, Carlier, H, Dubinsky, M C

Get full text

P956 Pregnancy outcomes after maternal or paternal exposure in the tofacitinib ulcerative colitis clinical programme by Mahadevan, U, Chaparro, M, Segovia Medina, M, Kulisek, N, Guo, X, Wu, J, Vranic, I, Diehl, A, Dubinsky, M C

Get full text

P1040 Comparative effectiveness of upadacitinib versus ustekinumab in patients with moderately to severely active Crohn’s disease: a matching-adjusted indirect comparison by Ma, C, Dubinsky, M C, Axelrad, J, Anyanwu, S, Tran, J, Lacerda, A, Joshi, N, Griffith, J

Get full text

Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases by Long, Millie D., Weaver, Kimberly N., Zhang, Xian, Chun, Kelly, Kappelman, Michael D., Watkins, R., Adler, J., Dubinsky, M.C., Kastl, A., Bousvaros, A., Strople, J.A., Cross, R.K., Higgins, P.D.R., Ungaro, R.C., Bewtra, M., Bellaguarda, E., Farraye, F.A., Boccieri, M.E., Firestine, A., Fernando, M., Bastidas, M., Zikry, M., Dai, X.

“…The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has disrupted health care and has resulted in high mortality rates.1 Vaccination is…”
Get full text

P138 Psychometric validation and interpretation of a patient-reported outcomes instrument to assess bowel urgency among adults with moderate to severe Ulcerative Colitis by Dubinsky, M C, Delbecque, L, Lewis, J, Hunter, T, Shan, M

Get full text

P186 Impact of tofacitinib maintenance therapy on key Ulcerative Colitis patient-reported outcomes of fatigue, urgency, abdominal pain and sexual dysfunction using IBDQ and SF-36 individual items as proxies by Dubinsky, M C, Gardiner, S, Hur, P, Guo, X, Paulissen, J, Cappelleri, J C, Bushmakin, A G, Panés, J

Get full text